Side-by-side research comparison of Ipamorelin and Sermorelin across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 1 head-to-head study plus 36 on Ipamorelin and 65 on Sermorelin.
| Ipamorelin | Sermorelin | |
|---|---|---|
| Drug class | ghrh secretagogue, ghrelin mimetic | ghrh analog |
| Studies in corpus | 36 | 65 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | other · 6 preclinical animal · 16 in vitro · 3 rct · 2 review · 1 | other · 20 rct · 11 cohort · 1 in vitro · 10 review · 2 preclinical animal · 10 |
| Studies with explicit sample size | 3 | 6 |
| Head-to-head studies in corpus | 1 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Ipamorelin and Sermorelin batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 2109 Ipamorelin batches across 690 manufacturers, 99.5% avg purity.
We tested 1049 Sermorelin batches across 399 manufacturers, 99.2% avg purity.
We hold deeper lab coverage on Ipamorelin (2109 batches tested). Ipamorelin edges ahead on average measured purity (99.5% vs 99.2%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both Ipamorelin and Sermorelin — the gold-standard direct comparison evidence.
For clinicians and individuals managing hypogonadism, this review positions GHS like ipamorelin as a potential next-frontier adjunctive therapy to testosterone, specifically for targeting body composition issues like stubborn fat and muscle loss. The key im…
Looking for vendor-level purity, endotoxin, and HPLC data on Ipamorelin or Sermorelin? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.